Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug

International Immunopharmacology

Volumn 1, Issue 12, 2001, Pages 2163-2171

  Suwaki, Toshimitsu ^a   Agrawal, Devendra K ^a   Townley, Robert G ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti allergic drugs; Asthma; Eosinophil; IPD; Suplatast tosilate; VCAM 1; VLA 4

Indexed keywords

BETA1 INTEGRIN; INTERLEUKIN 4; SUPLATAST TOSYLATE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC ASTHMA; ANTIGEN EXPRESSION; ARTICLE; ATTENUATION; CELL ADHESION; CELL FUNCTION; CELL STIMULATION; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; EOSINOPHIL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; TECHNIQUE; UMBILICAL VEIN;

ANTI-ALLERGIC AGENTS; ARYLSULFONATES; ASTHMA; CELL ADHESION; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; EOSINOPHILS; GENE EXPRESSION REGULATION; HUMANS; INTEGRIN ALPHA4BETA1; INTEGRINS; INTERLEUKIN-4; PLATELET ACTIVATING FACTOR; PULMONARY EOSINOPHILIA; RECEPTORS, LYMPHOCYTE HOMING; RESPIRATORY HYPERSENSITIVITY; SULFONIUM COMPOUNDS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0034779885     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00142-4     Document Type: Article

References (52)

1. Eosinophilic inflammation in asthma
2. Clinical aspects of eosinophilia in atopic disease
3. The role of eosinophils in the pathogenesis of asthma
4. Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway
5. Mechanisms of eosinophil recruitment
6. Eosinophilia
7. Expression of E-selectin, ICAM-1 and VCAM-1 on bronchial biopsies from allergic and non-allergic asthmatic patients
8. Increased adhesion to vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 of eosinophils from patients with asthma
9. Adhesion molecules in allergic inflammation
10. Anti-inflammatory effect of suplatast tosilate on mild asthma
11. Suplatast tosilate affects the initial increase in specific IgE and interleukin-4 during immunotherapy for perennial allergic rhinitis
12. Suplatast tosilate inhibits late response and airway inflammation in sensitized guinea pigs
13. Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs
14. Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (1) Regulation of murine IgE response
15. 2 cell-mediated murine peritoneal eosinophilia by antiallergic agents
16. 2 cell lines
17. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils
18. Attenuation of human leukocyte adherence to endothelial cell monolayers by tyrosine kinase inhibitors
19. Cell adhesion molecules and insulin-like growth factor-1 in vascular disease
20. A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration
21. Mechanisms of eosinophil adherence to cultured vascular endothelial cells. Eosinophils bind to the cytokine-induced ligand vascular cell adhesion molecule-1 via the very late activation antigen-4 integrin receptor
22. Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1
23. Leukocyte infiltration in allergic airway inflammation
24. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1
25. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells
26. Regulation of endothelial and mesothelial cell function by interleukin-13: Selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production
27. Mechanisms of selective leukocyte recruitment from whole blood on cytokine-activated endothelial cells under flow conditions
28. Comparison of adhesion molecule expression on light and normal-density eosinophils from patients with eosinophilia
29. Human eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is alpha 4 beta 1 (very late antigen-4) dependent
30. Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram
31. Selective regulation of expression of surface adhesion molecules Mac-1, L-selectin, and VLA-4 on human eosinophils and neutrophils
32. Alpha d beta 2 integrin is expressed on human eosinophils and functions as an alternative ligand for vascular cell adhesion molecule 1 (VCAM-1)
33. Granulocyte-macrophage colony-stimulating factor regulates the functional adhesive state of very late antigen-4 expressed by eosinophils
34. Differential regulation of eosinophil adhesion and transmigration by pulmonary microvascular endothelial cells
35. Interleukin-4 and lipopolysaccharide synergize to induce vascular cell adhesion molecule-1 expression in human lung microvascular endothelial cells
36. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils
37. Human eotaxin induces eosinophil extravasation through rat mesenteric venules: Role of alpha4 integrins and vascular cell adhesion molecule-1
38. Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep
39. Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation
40. Degranulation of eosinophils mediated by intercellular adhesion molecule-1 and its ligands is involved in adhesion molecule expression on endothelial cells-selective induction of VCAM-1
41. Endothelial cells upregulate eosinophil superoxide generation via VCAM-1 expression
42. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils
43. Modulation and induction of eosinophil chemotaxis by granulocyte-macrophage colony-stimulating factor and interleukin-3
44. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils
45. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils
46. Eosinophil accumulation induced by human interleukin-8 in the guinea-pig in vivo
47. In vivo priming of platelet-activating factor-induced eosinophil chemotaxis in allergic asthmatic individuals
48. PAF-induced eosinophil chemotaxis increases during an asthmatic attack and is inhibited by prednisolone in vivo and in vitro
49. Upregulation of formyl-peptide and interleukin-8-induced eosinophil chemotaxis in patients with allergic asthma
50. Pretreatment with rh-GMCSF, but not rh-IL3, enhances PAF-induced eosinophil accumulation in guinea-pig airways
51. Sensitization primes platelet-activating factor (PAF)-induced accumulation of eosinophils in mouse skin lesions: Contribution of cytokines to the response
52. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects